EichorEICHOR
Study identifier: NCT06592599 Synced from ClinicalTrials.gov · August 02, 2026
● Recruiting

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

Condition: Nasopharyngeal Carcinoma  ·  Sponsor: Stanford University

PhasePhase 2
Planned participants24
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Elizabeth Winters  ·  (650) 723-6372  ·  ewinters@stanford.edu

A. Dimitrios Colevas, MD  ·  650-704-8563  ·  colevas@stanford.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Stanford UniversityPalo Alto, California, United StatesRecruiting

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06592599